Document is current
Any future updates will be listed below
-
Authors
Lassen, Annika Sofia https://orcid.org/0009-0008-1071-5452
Petersen, Therese Lockenwitz https://orcid.org/0000-0002-3132-9568
Kirkegaard, Helene https://orcid.org/0000-0001-6877-916X
Laursen, Mathilde Grøn https://orcid.org/0000-0003-2319-957X
Østergaard, Jane Nautrup https://orcid.org/0000-0002-0627-1237
Ryom, Knud https://orcid.org/0000-0001-5947-3038
- License Information
-
More Information
Article History
Received: 5 March 2025
Accepted: 22 January 2026
First Online: 1 April 2026
Declarations
:
: The Danish Scientific Ethics Committee approved the feasibility study in Havndal with the clinical trial number 1-10-72-283-21. The Danish Ethical Committee reviewed the feasibility study at Moen and concluded that formal ethics approval was not required. The study is conducted in accordance with the principles of the Declaration of Helsinki, and all methods were carried out in accordance with relevant guidelines and regulations. Informed verbal consents to participate were given from all respondents.
: All participants were informed and consented to publication of collected data..
: The authors declared no competing interests. ASL, MGL, HK and JNØ are employed at Steno Diabetes Center Aarhus, and TLP is employed at Steno Diabetes Center Copenhagen. Both public hospitals and research institutions in the Central Denmark Region and the capital Region of Denmark, are both partly funded by an unrestricted grant from the Novo Nordisk Foundation. The Novo Nordisk Foundation was not involved in the design or conduct of this study.
